Literature DB >> 30448912

Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.

Martina Mandarano1, Guido Bellezza2, Maria Laura Belladonna3, Benoit J Van den Eynde4, Rita Chiari5, Jacopo Vannucci6, Giada Mondanelli3, Vienna Ludovini5, Ivana Ferri2, Fortunato Bianconi7, Rachele Del Sordo2, Lucio Cagini6, Elisa Albini3, Giulio Metro5, Francesco Puma6, Angelo Sidoni2.   

Abstract

Several cancers, especially non-small cell lung cancer (NSCLC), are able to escape the immunosurveillance of tumor-infiltrating lymphocytes (TILs); among the molecules involved, the indoleamine 2,3-dioxygenase 1 (IDO-1) and the programmed cell death ligand-1 (PD-L1) play a crucial role. These aspects are of great interest in the current immunotherapeutic era, therefore the current study analyses the TILs, IDO-1, and PD-L1 interactions and their correlations with clinicopathological parameters and prognosis in NSCLC. One hundred ninety-three NSCLC surgical specimens, formalin-fixed, and paraffin-embedded were assessed for TILs density, TILs localization, IDO-1 (clone 4.16H1), and PD-L1 (clone E1L3N) immunohistochemical expressions. This data was correlated with clinicopathological parameters, disease free, and overall survivals. IDO-1 and PD-L1 high expressions were related to the solid pattern of adenocarcinomas (respectively p = 0.036 and p = 0.026); high PD-L1 expression was correlated with squamous histotype (p = 0.048). IDO-1 overexpression correlated with former smokers (p = 0.041), higher adenocarcinoma stages (p = 0.039), and with both higher TILs density and PD-L1 expression (respectively p = 0.025 and p = 0.0003). A better prognosis was associated with TILs intratumoral or mixed localizations (p = 0.029). TILs localization affects NSCLC prognosis; the higher expression of IDO-1 and PD-L1 in poorly differentiated and more aggressive lung adenocarcinomas, as well as the correlation between high PD-L1 expression and squamous cell histotype, confirm the more efficient immunoescaping of these NSCLC subgroups.

Entities:  

Keywords:  IDO-1; Immunotherapy; Non-small cell lung cancer; PD-L1; Tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2018        PMID: 30448912     DOI: 10.1007/s00428-018-2483-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  50 in total

1.  [The expression and significance of indoleamine -2,3 -dioxygenase in non-small cell lung cancer cell.].

Authors:  Qichao Xie; Lingli Wang; Bo Zhu; Yali Wang; Jianteng Gu; Zhengtang Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2008-02-20

2.  Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer.

Authors:  Simonetta Astigiano; Barbara Morandi; Roberta Costa; Luca Mastracci; Antonella D'Agostino; Giovanni Battista Ratto; Giovanni Melioli; Guido Frumento
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

Review 3.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

4.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

5.  High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.

Authors:  Jocelyne Jacquemier; François Bertucci; Pascal Finetti; Benjamin Esterni; Emmanuelle Charafe-Jauffret; Marie-Laure Thibult; Gilles Houvenaeghel; Benoit Van den Eynde; Daniel Birnbaum; Daniel Olive; Luc Xerri
Journal:  Int J Cancer       Date:  2012-01-01       Impact factor: 7.396

6.  Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms.

Authors:  Enrico Ruffini; Sofia Asioli; Pier Luigi Filosso; Paraskevas Lyberis; Maria Cristina Bruna; Luigia Macrì; Lorenzo Daniele; Alberto Oliaro
Journal:  Ann Thorac Surg       Date:  2009-02       Impact factor: 4.330

Review 7.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 8.  Blocking IDO activity to enhance anti-tumor immunity.

Authors:  David H Munn
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

9.  Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer.

Authors:  L Ferdinande; C Decaestecker; L Verset; A Mathieu; X Moles Lopez; A-M Negulescu; T Van Maerken; I Salmon; C A Cuvelier; P Demetter
Journal:  Br J Cancer       Date:  2011-11-22       Impact factor: 7.640

10.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.

Authors:  K Hiraoka; M Miyamoto; Y Cho; M Suzuoki; T Oshikiri; Y Nakakubo; T Itoh; T Ohbuchi; S Kondo; H Katoh
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

View more
  13 in total

1.  IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas.

Authors:  Guanglin Cui; Zhenfeng Li; Jingli Ren; Aping Yuan
Journal:  Virchows Arch       Date:  2019-05-06       Impact factor: 4.064

2.  Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.

Authors:  Martina Mandarano; Elena Orecchini; Guido Bellezza; Jacopo Vannucci; Vienna Ludovini; Sara Baglivo; Francesca Romana Tofanetti; Rita Chiari; Elisabetta Loreti; Francesco Puma; Angelo Sidoni; Maria Laura Belladonna
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

3.  [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].

Authors:  Qingqing Hang; Hangjie Ying; Guoping Cheng; Shifeng Yang; Jianan Jin; Yamei Chen; Qixun Chen; Youhua Jiang; Qiang Zhao; Min Fang; Ming Chen; Xiaojing Lai
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-10-20

Review 4.  IDO Expression in Cancer: Different Compartment, Different Functionality?

Authors:  Annabel Meireson; Michael Devos; Lieve Brochez
Journal:  Front Immunol       Date:  2020-09-24       Impact factor: 7.561

Review 5.  Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.

Authors:  Yaru Tian; Xiaoyang Zhai; Weiwei Yan; Hui Zhu; Jinming Yu
Journal:  Cancer Med       Date:  2020-11-24       Impact factor: 4.452

6.  High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.

Authors:  Vienna Ludovini; Fortunato Bianconi; Annamaria Siggillino; Jacopo Vannucci; Sara Baglivo; Valeria Berti; Francesca Romana Tofanetti; Maria Sole Reda; Guido Bellezza; Martina Mandarano; Maria Laura Belladonna; Giulio Metro; Rita Chiari; Angelo Sidoni; Francesco Puma; Vincenzo Minotti; Fausto Roila
Journal:  Genes (Basel)       Date:  2021-02-15       Impact factor: 4.096

7.  Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.

Authors:  Martina Mandarano; Guido Bellezza; Maria Laura Belladonna; Jacopo Vannucci; Alessio Gili; Ivana Ferri; Chiara Lupi; Vienna Ludovini; Giulia Falabella; Giulio Metro; Giada Mondanelli; Rita Chiari; Lucio Cagini; Fabrizio Stracci; Fausto Roila; Francesco Puma; Claudia Volpi; Angelo Sidoni
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

8.  Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.

Authors:  Martina Vrankar; Izidor Kern; Karmen Stanic
Journal:  Radiat Oncol       Date:  2020-10-29       Impact factor: 3.481

9.  The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?

Authors:  Pinar Bulutay; Pinar Firat; Emine Handan Zeren; Suat Erus; Serhan Tanju; Mustafa Şükrü Dilege
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 0.973

Review 10.  Biomedical Applications of Non-Small Cell Lung Cancer Spheroids.

Authors:  Julian M Rozenberg; Gleb I Filkov; Alexander V Trofimenko; Evgeny A Karpulevich; Vladimir D Parshin; Valery V Royuk; Marina I Sekacheva; Mikhail O Durymanov
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.